The present invention provides a hollow borosilicate microparticle contrast media for use in CT imaging with shell material containing less than 8% oxides of non-silicon elements with atomic number greater than 10. In an exemplary embodiment, the invention provides an enteric contrast medium formulation which provides CT numbers distinct from those of water, soft tissue, and fat. In an exemplary embodiment, the invention provides an enteric contrast medium formulation that shows iodine concentrations less than 1.0 mg iodine/mL at dual energy CT or multi-energy CT image reformations. An exemplary formulation comprises, (a) an enteric contrast medium comprising a hollow borosilicate microparticle suspended in water. Exemplary hollow borosilicate microparticle has a true gravity between 0.1 and 0.4 g/cm.sup.3. In various embodiments, the hollow borosilicate microparticle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast material is incorporated into a pharmaceutically acceptable carrier in which the material is suspended. In an exemplary embodiment, the hollow borosilicate microparticle comprises 1% to 15% of the weight of an aqueous contrast material formulation. The invention also provides methods for imaging of the abdomen and pelvis by CT imaging contemporaneously with the delivery of the hollow borosilicate microparticle contrast material into the bowel lumen.

The present invention provides a hollow borosilicate microparticle contrast media for use in CT imaging with shell material containing less than 8% oxides of non-silicon elements with atomic number greater than 10. In an exemplary embodiment, the invention provides an enteric contrast medium formulation which provides CT numbers distinct from those of water, soft tissue, and fat. In an exemplary embodiment, the invention provides an enteric contrast medium formulation that shows iodine concentrations less than 1.0 mg iodine/mL at dual energy CT or multi-energy CT image reformations. An exemplary formulation comprises, (a) an enteric contrast medium comprising a hollow borosilicate microparticle suspended in water. Exemplary hollow borosilicate microparticle has a true gravity between 0.1 and 0.4 g/cm.sup.3. In various embodiments, the hollow borosilicate microparticle is suspended in aqueous media by an agent compatible with enteric administration of the formulation to a subject in need of such administration. In an exemplary embodiment, the contrast material is incorporated into a pharmaceutically acceptable carrier in which the material is suspended. In an exemplary embodiment, the hollow borosilicate microparticle comprises 1% to 15% of the weight of an aqueous contrast material formulation. The invention also provides methods for imaging of the abdomen and pelvis by CT imaging contemporaneously with the delivery of the hollow borosilicate microparticle contrast material into the bowel lumen.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

The invention relates to a novel use of ultrafine nanoparticles, of use as a diagnostic, therapeutic or theranostic agent, characterized by their mode of administration via the airways. The invention is also directed toward the applications which follow from this novel mode of administration, in particular for imaging the lungs, and the diagnosis or prognosis of pathological pulmonary conditions. In the therapeutic field, the applications envisioned are those of radiosensitizing or radioactive agents for radiotherapy (and optionally curietherapy), or for neutron therapy, or of agents for PDT (photodynamic therapy), in particular for the treatment of lung tumors.

The liquid vehicles can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.

The liquid vehicles can be used to create dilute solutions of water-soluble pharmaceutical or non-pharmaceutical oral contrast agents. The liquid vehicles are formulated to provide desired osmolalities, viscosities, pH, and taste masking capabilities to match the particular intentions of the user and to complement the inherent differences in the various oral contrast agents. The liquid vehicles comprise an aqueous medium, an osmotic agent to adjust osmolality, a buffering agent, a viscosity agent, and sweeteners and flavoring agents to improve palatability.

The invention relates to a system and a method for determining a characteristic of a blood vessel portion, which comprises blood including a contrast agent exhibiting resonant absorption of x-ray photons at a specific energy. The system comprises a tunable monochromatic x-ray source (21) emitting x-ray radiation, an x-ray detector device (22) for detecting the x-ray radiation after it has travelled through the blood vessel portion. A control unit (26) varies a tuning of the x-ray source (21) to vary the energy of the x-ray radiation emitted by the x-ray source (21), and an evaluation unit (27) determines a tuning of the x-ray source (21) at which nuclear resonant absorption of the x-ray radiation incident onto the blood vessel portion occurs and estimates the characteristic on the basis of the determined tuning. The characteristic may particularly be the blood velocity in the blood vessel portion.

The invention relates to a system and a method for determining a characteristic of a blood vessel portion, which comprises blood including a contrast agent exhibiting resonant absorption of x-ray photons at a specific energy. The system comprises a tunable monochromatic x-ray source (21) emitting x-ray radiation, an x-ray detector device (22) for detecting the x-ray radiation after it has travelled through the blood vessel portion. A control unit (26) varies a tuning of the x-ray source (21) to vary the energy of the x-ray radiation emitted by the x-ray source (21), and an evaluation unit (27) determines a tuning of the x-ray source (21) at which nuclear resonant absorption of the x-ray radiation incident onto the blood vessel portion occurs and estimates the characteristic on the basis of the determined tuning. The characteristic may particularly be the blood velocity in the blood vessel portion.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.

The disclosure herein relates to systems, methods, and devices for medical image analysis, diagnosis, risk stratification, decision making and/or disease tracking. In some embodiments, the systems, devices, and methods described herein are configured to analyze non-invasive medical images of a subject to automatically and/or dynamically identify one or more features, such as plaque and vessels, and/or derive one or more quantified plaque parameters, such as radiodensity, radiodensity composition, volume, radiodensity heterogeneity, geometry, location, perform computational fluid dynamics analysis, facilitate assessment of risk of heart disease and coronary artery disease, enhance drug development, determine a CAD risk factor goal, provide atherosclerosis and vascular morphology characterization, and determine indication of myocardial risk, and/or the like. In some embodiments, the systems, devices, and methods described herein are further configured to generate one or more assessments of plaque-based diseases from raw medical images using one or more of the identified features and/or quantified parameters.